Clinical Trial Update: A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ASP2138 in pancreatic ductal adenocarcinoma, given before surgery and followed by chemotherapy, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• ASP2138 (ASP2138)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: RECRUITING